68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid.

Abstract

The management of neuroendocrine tumours is challenging when curative surgery is ruled out because of distant metastases. We report a case of gastrointestinal carcinoid with bilateral ovarian metastases in a 50-year-old female who received octreotide therapy followed by peptide receptor radionuclide therapy and surgery thereafter. Somatostatin receptor expression on neuroendocrine tumours has implications in diagnosis and therapy. (68)Ga-DOTA-NOC PET is a recent advancement in the field of somatostatin receptor imaging. The lesions which demonstrate tracer uptake on positron emission tomographic studies can be further planned for treatment with octreotide and (177)Lu-DOTA-TATE. The case in discussion responded well to non-invasive treatment options before proceeding to definitive surgical management.

• Authors: Suhas Singla, Santosh Gupta, Rama Mohan Reddy, Prashant Durgapal, C S Bal
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 42 Issue 12 Pg. 1202-6 (Dec 2012) ISSN: 1465-3621 [Electronic] England
• PMID: 23107835 (Publication Type: Case Reports, Journal Article)

Chemical References

• 68Ga-DOTANOC
• Antineoplastic Agents
• Organometallic Compounds
• Radiopharmaceuticals
• Receptors, Somatostatin
• lutetium Lu 177 dotatate
• Octreotide

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoid Tumor (diagnostic imaging, radiotherapy, secondary)
• Female
• Gastrointestinal Neoplasms (diagnostic imaging, pathology, radiotherapy)
• Humans
• Middle Aged
• Octreotide (analogs & derivatives, therapeutic use)
• Organometallic Compounds
• Ovarian Neoplasms (diagnostic imaging, radiotherapy, secondary)
• Positron-Emission Tomography
• Radiopharmaceuticals
• Receptors, Somatostatin (metabolism, therapeutic use)